Compounded semaglutide vs brand name Wegovy: what is the real difference?

Short answer

• Wegovy (Novo Nordisk) is the FDA‑approved, factory‑made semaglutide formulation for chronic weight management (titrated to 2.4 mg weekly). It has standardized manufacturing, stability testing, controlled packaging (prefilled pens), and robust clinical-trial evidence for safety and effectiveness.
• “Compounded semaglutide” is a pharmacy‑made version prepared when a prescriber requests it. It is not FDA‑approved, may come in vials, syringes or different concentrations, and is subject to more variable quality, testing, stability, and sterility practices. It can be cheaper or more available, but carries greater risk of inconsistent potency or contamination.

Key differences (why they matter)

• Regulatory status and evidence
  • Wegovy: FDA approved for weight loss based on large phase‑3 trials showing efficacy and a known safety profile.
  • Compounded: Not FDA‑approved as a finished drug; there are no large clinical trials on a given compounded product, so safety/efficacy depend on how closely it matches the approved product and the quality of compounding.
• Manufacturing quality and testing
  • Wegovy: Made under GMP controls, batch‑tested for potency, sterility, impurities, and stability.
  • Compounded: Quality depends on the pharmacy. Some reputable 503B outsourcing facilities follow strict standards and are inspected, but many 503A compounding pharmacies are smaller and may not run the same lot testing.
• Formulation, dosing and delivery
  • Wegovy: Supplied in prefilled pens with fixed concentrations and a validated titration schedule (up to 2.4 mg weekly).
  • Compounded: May be supplied as vials, syringes or pens with variable concentrations. That increases risk of dosing errors when drawing doses or converting between formulations.
• Stability and sterility
  • Wegovy: Manufacturer provides validated storage instructions and expiration dating.
  • Compounded: Often has shorter beyond‑use dating; some require reconstitution, and sterility/particulate control may vary.
• Safety and traceability
  • Wegovy: Clear lot traceability and adverse‑event surveillance.
  • Compounded: Harder to trace batches; higher risk of contaminated product or incorrect API source.
• Cost and availability
  • Wegovy: Expensive and sometimes in short supply; insurance coverage may be limited.
  • Compounded: Often cheaper and easier to obtain, which is why patients use it — but you trade lower cost for greater uncertainty about quality and legality in some cases.

Practical advice if you’re deciding

• Prefer Wegovy when you can: it’s the only option with the specific FDA approval and consistent manufacturing.
• If considering compounded semaglutide (because of cost or access), do this:
  • Use a reputable source: prefer an FDA‑registered 503B outsourcing facility or a pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB).
  • Ask for documentation: certificate of analysis (COA) for the API, sterility testing, potency testing, lot number, and written beyond‑use dating and storage instructions.
  • Confirm formulation and concentration so dosing is exact; get clear administration training.
  • Avoid purchasing from online sellers that won’t provide a prescription, COA, or pharmacy credentials.
• Discuss safety with your prescriber: semaglutide can interact with diabetes medications (risk of hypoglycemia), causes GI side effects, and requires monitoring for rare adverse effects.

Alternatives to discuss with your clinician

• Ozempic (semaglutide, Novo Nordisk) — approved for type 2 diabetes; sometimes used off‑label for weight loss in lower doses.
• Zepbound (tirzepatide, Eli Lilly) and Mounjaro (tirzepatide for diabetes) — tirzepatide has strong weight‑loss data and a separate approved product for weight management (Zepbound).

Bottom line Wegovy is the safer, standardized, evidence‑backed choice. Compounded semaglutide can be a lower‑cost or available alternative but carries real risks around potency, sterility, stability and regulatory oversight. If you’re considering a compounded product, insist on an accredited, transparent pharmacy and documentation, and talk it over with your prescribing clinician.